AbbVie and Harvard University have announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.   This collaboration aims to integrate fundamental biology into the preclinical and clinical development of new therapies for viral diseases that address a variety of therapeutic...